A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Mallinckrodt · Hepatorenal Syndrome
Phase 3
Completed
196
2022-11
Industry sponsor intelligence
MallinckrodtClinical Pipeline.
Lead-sponsor view of Mallinckrodt's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 2
- Recruiting
- 0
- Active
- 0
- Completed
- 2
- Results posted
- 2
- Avg enrollment
- 248
Pipeline overview
Programs by phase and activity.
Velocity
Mallinckrodt trials by start year
Study start year · indexed snapshot
Development
Trials by phase
2phase labels
Early Phase 10
Phase 10
Phase 20
Phase 32
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Terlipressin → | 2 | 0 | 0 | 2 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1
Mallinckrodt · Hepatorenal Syndrome
Phase 3
Completed
300
2022-11
Search sponsor records
All Mallinckrodt studies.
This page groups studies where Mallinckrodt is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
2 matching studies
Last registry update first